Key Developments: Hisamitsu Pharmaceutical Co Inc (HTSUF.PK)
49.00USD
14 Jun 2013
$-2.55 (-4.94%)
$51.55
$49.00
$49.00
$49.00
100
2
$53.00
$46.87
Latest Key Developments (Source: Significant Developments)
R&I Withdraws Rating on HISAMITSU PHARMACEUTICAL CO INC
Rating and Investment Information, Inc. (R&I) announced that it has withdrawn the rating on HISAMITSU PHARMACEUTICAL CO INC. The issuer rating has been set at "A". Full Article
HISAMITSU PHARMACEUTICAL CO INC Raises Mid-year Consolidated Outlook for FY 2013
HISAMITSU PHARMACEUTICAL CO INC announced that it has raised its mid-year consolidated outlook for revenue from JPY 71,100 million to JPY 71,900 million, operating profit from JPY 10,200 million to JPY 13,200 million, ordinary profit from JPY 13,400 million to JPY 16,400 million, net profit from JPY 7,900 million to JPY 9,300 million, and earnings per share from JPY 92.22 to JPY 108.56, for the fiscal year ending February 2013. The Company raised its mid-year consolidated outlook mainly due to the decrease in research and management costs. Full Article
Hisamitsu Pharmaceutical Co., Ltd. to Dissolve Subsidiary and Sub-subsidiary
Hisamitsu Pharmaceutical Co., Ltd. announced that it has decided to dissolve its Saga-based 50%-owned sub-subsidiary, which had been engaged in the manufacturing and sale of medical products, as well as its Sago-based 50%-owned, which had been engaged in the trading and management of real estates. The liquidation will start after June 2012. The sub-subsidiary and subsidiary are now dormant companies. Full Article
Hisamitsu Pharmaceutical Co., Ltd. to Establish Joint Venture with sanofi-aventis K.K.
Hisamitsu Pharmaceutical Co., Ltd. announced that it has decided to establish a Tokyo-located joint venture SANOFI-HISAMITSU K.K., which will be engaged in the marketing of over the counter drug business, with sanofi-aventis K.K., effective July 2, 2012. sanofi-aventis and the company will each hold a 51% and 49% stake in the joint venture. Full Article
Hisamitsu Pharmaceutical Co., Ltd. Announces Result of Phase III Clinical Trial for HTU-520
Hisamitsu Pharmaceutical Co., Ltd. announced the result of the domestic phase III clinical trial for HTU-520, which is used as treatment drug for trichophytosis unguium. The phase III clinical trial confirmed the dose-response and the safety of the drug. Full Article
Hisamitsu Pharmaceutical Co., Ltd. Forms Capital and Business Alliance with Yutoku Pharmaceutical lnd.Co., Ltd.
Hisamitsu Pharmaceutical Co., Ltd. announced that it has formed a capital and business alliance with Yutoku Pharmaceutical lnd.Co., Ltd. on January 17, 2012. Hisamitsu Pharmaceutical has acquired 18,000 shares (15.00% stake) of Yutoku Pharmaceutical lnd.Co., Ltd. on January 17, 2012. The two companies will collaborate in medicine manufacturing technology and sales know-how business. Full Article
R&I Affirms Hisamitsu Pharmaceutical Co., Ltd.'s Rating at "A"; Rating Outlook Stable
Rating and Investment Information, Inc. (R&I) announced that it has affirmed the rating on Hisamitsu Pharmaceutical Co., Ltd. at "A". The rating outlook is stable. Full Article
Hisamitsu Pharmaceutical Co., Ltd. Issues FY 2012 Outlook; Amends Midterm and Year-end Dividend Outlook for FY Ending February 2012
Hisamitsu Pharmaceutical Co., Ltd. announced that it has issued its consolidated mid-year outlook for revenue of JPY 69,500 million, operating profit of JPY 13,300 million, ordinary profit of JPY 16,200 million, net profit of JPY 7,700 million and earning per share of JPY 89.64 for the fiscal year ending February 29, 2012. The Company also issued its consolidated full-year outlook for revenue of JPY 142,400 million, operating profit of JPY 24,000 million, ordinary profit of JPY 30,500 million, net profit of JPY 17,200 million and earning per share of JPY 200.24 for the fiscal year ending March 31, 2012. According to I/B/E/S Estimates, analysts on average are expecting the Company to report full-year revenue of JPY 141.57 billion and net profit of JPY 18.53 billion. The Company also amends its midterm and year-end dividend outlook from an undetermined value, which were announced on April 8, 2011, to JPY 35.00 per share, respectively, for the same fiscal year. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
